nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefuroxime—Liver disorder—Methotrexate—muscle cancer	0.00816	0.00816	CcSEcCtD
Cefuroxime—Vaginal discharge—Doxorubicin—muscle cancer	0.00791	0.00791	CcSEcCtD
Cefuroxime—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.00775	0.00775	CcSEcCtD
Cefuroxime—Pancytopenia—Dactinomycin—muscle cancer	0.00764	0.00764	CcSEcCtD
Cefuroxime—Neutropenia—Dactinomycin—muscle cancer	0.00752	0.00752	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.00711	0.00711	CcSEcCtD
Cefuroxime—Stomatitis—Dactinomycin—muscle cancer	0.00699	0.00699	CcSEcCtD
Cefuroxime—Pancytopenia—Vincristine—muscle cancer	0.00683	0.00683	CcSEcCtD
Cefuroxime—Dysuria—Vincristine—muscle cancer	0.00672	0.00672	CcSEcCtD
Cefuroxime—Neutropenia—Vincristine—muscle cancer	0.00672	0.00672	CcSEcCtD
Cefuroxime—Agranulocytosis—Dactinomycin—muscle cancer	0.00669	0.00669	CcSEcCtD
Cefuroxime—Hepatitis—Dactinomycin—muscle cancer	0.00644	0.00644	CcSEcCtD
Cefuroxime—Stomatitis—Vincristine—muscle cancer	0.00625	0.00625	CcSEcCtD
Cefuroxime—Musculoskeletal stiffness—Methotrexate—muscle cancer	0.0062	0.0062	CcSEcCtD
Cefuroxime—Sweating—Vincristine—muscle cancer	0.00614	0.00614	CcSEcCtD
Cefuroxime—Erythema multiforme—Dactinomycin—muscle cancer	0.00609	0.00609	CcSEcCtD
Cefuroxime—Cramp muscle—Etoposide—muscle cancer	0.00607	0.00607	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00607	0.00607	CcSEcCtD
Cefuroxime—Injection site pain—Doxorubicin—muscle cancer	0.0059	0.0059	CcSEcCtD
Cefuroxime—Hepatic enzyme increased—Methotrexate—muscle cancer	0.00588	0.00588	CcSEcCtD
Cefuroxime—Chills—Dactinomycin—muscle cancer	0.00578	0.00578	CcSEcCtD
Cefuroxime—Urinary tract disorder—Vincristine—muscle cancer	0.00568	0.00568	CcSEcCtD
Cefuroxime—Urethral disorder—Vincristine—muscle cancer	0.00564	0.00564	CcSEcCtD
Cefuroxime—Erythema—Dactinomycin—muscle cancer	0.00561	0.00561	CcSEcCtD
Cefuroxime—Vaginal inflammation—Methotrexate—muscle cancer	0.00556	0.00556	CcSEcCtD
Cefuroxime—Pancytopenia—Etoposide—muscle cancer	0.00553	0.00553	CcSEcCtD
Cefuroxime—Neutropenia—Etoposide—muscle cancer	0.00545	0.00545	CcSEcCtD
Cefuroxime—Vaginal infection—Methotrexate—muscle cancer	0.00525	0.00525	CcSEcCtD
Cefuroxime—Angiopathy—Vincristine—muscle cancer	0.00522	0.00522	CcSEcCtD
Cefuroxime—Aplastic anaemia—Methotrexate—muscle cancer	0.00522	0.00522	CcSEcCtD
Cefuroxime—Infestation NOS—Etoposide—muscle cancer	0.00519	0.00519	CcSEcCtD
Cefuroxime—Infestation—Etoposide—muscle cancer	0.00519	0.00519	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00515	0.00515	CcSEcCtD
Cefuroxime—Renal failure—Etoposide—muscle cancer	0.0051	0.0051	CcSEcCtD
Cefuroxime—Blood bilirubin increased—Doxorubicin—muscle cancer	0.00509	0.00509	CcSEcCtD
Cefuroxime—Stomatitis—Etoposide—muscle cancer	0.00506	0.00506	CcSEcCtD
Cefuroxime—Jaundice—Etoposide—muscle cancer	0.00506	0.00506	CcSEcCtD
Cefuroxime—Creatinine increased—Doxorubicin—muscle cancer	0.00506	0.00506	CcSEcCtD
Cefuroxime—Mouth ulceration—Methotrexate—muscle cancer	0.00503	0.00503	CcSEcCtD
Cefuroxime—Leukopenia—Dactinomycin—muscle cancer	0.00502	0.00502	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Etoposide—muscle cancer	0.00491	0.00491	CcSEcCtD
Cefuroxime—Agranulocytosis—Etoposide—muscle cancer	0.00485	0.00485	CcSEcCtD
Cefuroxime—Vaginal inflammation—Doxorubicin—muscle cancer	0.00481	0.00481	CcSEcCtD
Cefuroxime—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.00481	0.00481	CcSEcCtD
Cefuroxime—Salivary hypersecretion—Doxorubicin—muscle cancer	0.00468	0.00468	CcSEcCtD
Cefuroxime—Thrombophlebitis—Methotrexate—muscle cancer	0.00466	0.00466	CcSEcCtD
Cefuroxime—Colitis—Doxorubicin—muscle cancer	0.00462	0.00462	CcSEcCtD
Cefuroxime—Urinary tract disorder—Etoposide—muscle cancer	0.0046	0.0046	CcSEcCtD
Cefuroxime—Agitation—Vincristine—muscle cancer	0.0046	0.0046	CcSEcCtD
Cefuroxime—Candida infection—Doxorubicin—muscle cancer	0.0046	0.0046	CcSEcCtD
Cefuroxime—Urethral disorder—Etoposide—muscle cancer	0.00457	0.00457	CcSEcCtD
Cefuroxime—Blood urea increased—Doxorubicin—muscle cancer	0.00454	0.00454	CcSEcCtD
Cefuroxime—Vaginal infection—Doxorubicin—muscle cancer	0.00454	0.00454	CcSEcCtD
Cefuroxime—Aplastic anaemia—Doxorubicin—muscle cancer	0.00452	0.00452	CcSEcCtD
Cefuroxime—Leukopenia—Vincristine—muscle cancer	0.00448	0.00448	CcSEcCtD
Cefuroxime—Thrombocytopenia—Dactinomycin—muscle cancer	0.00448	0.00448	CcSEcCtD
Cefuroxime—Erythema multiforme—Etoposide—muscle cancer	0.00441	0.00441	CcSEcCtD
Cefuroxime—Anorexia—Dactinomycin—muscle cancer	0.00436	0.00436	CcSEcCtD
Cefuroxime—Mouth ulceration—Doxorubicin—muscle cancer	0.00435	0.00435	CcSEcCtD
Cefuroxime—Convulsion—Vincristine—muscle cancer	0.00434	0.00434	CcSEcCtD
Cefuroxime—Angiopathy—Etoposide—muscle cancer	0.00423	0.00423	CcSEcCtD
Cefuroxime—Immune system disorder—Etoposide—muscle cancer	0.00421	0.00421	CcSEcCtD
Cefuroxime—Chills—Etoposide—muscle cancer	0.00418	0.00418	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00417	0.00417	CcSEcCtD
Cefuroxime—Anaphylactic shock—Vincristine—muscle cancer	0.00409	0.00409	CcSEcCtD
Cefuroxime—Thrombophlebitis—Doxorubicin—muscle cancer	0.00404	0.00404	CcSEcCtD
Cefuroxime—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.00402	0.00402	CcSEcCtD
Cefuroxime—Thrombocytopenia—Vincristine—muscle cancer	0.004	0.004	CcSEcCtD
Cefuroxime—Hepatic function abnormal—Doxorubicin—muscle cancer	0.004	0.004	CcSEcCtD
Cefuroxime—Decreased appetite—Dactinomycin—muscle cancer	0.00398	0.00398	CcSEcCtD
Cefuroxime—Hyperhidrosis—Vincristine—muscle cancer	0.00395	0.00395	CcSEcCtD
Cefuroxime—Pain—Dactinomycin—muscle cancer	0.00391	0.00391	CcSEcCtD
Cefuroxime—Muscle spasms—Etoposide—muscle cancer	0.0039	0.0039	CcSEcCtD
Cefuroxime—Anorexia—Vincristine—muscle cancer	0.0039	0.0039	CcSEcCtD
Cefuroxime—Irritability—Methotrexate—muscle cancer	0.00385	0.00385	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00374	0.00374	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00372	0.00372	CcSEcCtD
Cefuroxime—Renal impairment—Doxorubicin—muscle cancer	0.00367	0.00367	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00363	0.00363	CcSEcCtD
Cefuroxime—Leukopenia—Etoposide—muscle cancer	0.00363	0.00363	CcSEcCtD
Cefuroxime—Abdominal pain—Dactinomycin—muscle cancer	0.00362	0.00362	CcSEcCtD
Cefuroxime—Body temperature increased—Dactinomycin—muscle cancer	0.00362	0.00362	CcSEcCtD
Cefuroxime—Decreased appetite—Vincristine—muscle cancer	0.00355	0.00355	CcSEcCtD
Cefuroxime—Cough—Etoposide—muscle cancer	0.00354	0.00354	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Vincristine—muscle cancer	0.00353	0.00353	CcSEcCtD
Cefuroxime—Convulsion—Etoposide—muscle cancer	0.00352	0.00352	CcSEcCtD
Cefuroxime—Pain—Vincristine—muscle cancer	0.0035	0.0035	CcSEcCtD
Cefuroxime—Chest pain—Etoposide—muscle cancer	0.00345	0.00345	CcSEcCtD
Cefuroxime—Eosinophilia—Methotrexate—muscle cancer	0.00345	0.00345	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00343	0.00343	CcSEcCtD
Cefuroxime—Hypersensitivity—Dactinomycin—muscle cancer	0.00337	0.00337	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Vincristine—muscle cancer	0.00334	0.00334	CcSEcCtD
Cefuroxime—Pancytopenia—Methotrexate—muscle cancer	0.00331	0.00331	CcSEcCtD
Cefuroxime—Anaphylactic shock—Etoposide—muscle cancer	0.00331	0.00331	CcSEcCtD
Cefuroxime—Blood creatinine increased—Doxorubicin—muscle cancer	0.00327	0.00327	CcSEcCtD
Cefuroxime—Dysuria—Methotrexate—muscle cancer	0.00326	0.00326	CcSEcCtD
Cefuroxime—Neutropenia—Methotrexate—muscle cancer	0.00326	0.00326	CcSEcCtD
Cefuroxime—Thrombocytopenia—Etoposide—muscle cancer	0.00324	0.00324	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Methotrexate—muscle cancer	0.00324	0.00324	CcSEcCtD
Cefuroxime—Tachycardia—Etoposide—muscle cancer	0.00323	0.00323	CcSEcCtD
Cefuroxime—Body temperature increased—Vincristine—muscle cancer	0.00323	0.00323	CcSEcCtD
Cefuroxime—Abdominal pain—Vincristine—muscle cancer	0.00323	0.00323	CcSEcCtD
Cefuroxime—Skin disorder—Etoposide—muscle cancer	0.00322	0.00322	CcSEcCtD
Cefuroxime—Hyperhidrosis—Etoposide—muscle cancer	0.0032	0.0032	CcSEcCtD
Cefuroxime—Anorexia—Etoposide—muscle cancer	0.00316	0.00316	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.00315	0.00315	CcSEcCtD
Cefuroxime—Diarrhoea—Dactinomycin—muscle cancer	0.00313	0.00313	CcSEcCtD
Cefuroxime—Drowsiness—Methotrexate—muscle cancer	0.00311	0.00311	CcSEcCtD
Cefuroxime—Infestation NOS—Methotrexate—muscle cancer	0.00311	0.00311	CcSEcCtD
Cefuroxime—Infestation—Methotrexate—muscle cancer	0.00311	0.00311	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00308	0.00308	CcSEcCtD
Cefuroxime—Renal failure—Methotrexate—muscle cancer	0.00306	0.00306	CcSEcCtD
Cefuroxime—Stomatitis—Methotrexate—muscle cancer	0.00303	0.00303	CcSEcCtD
Cefuroxime—Hypersensitivity—Vincristine—muscle cancer	0.00301	0.00301	CcSEcCtD
Cefuroxime—Eosinophilia—Doxorubicin—muscle cancer	0.00299	0.00299	CcSEcCtD
Cefuroxime—Sweating—Methotrexate—muscle cancer	0.00298	0.00298	CcSEcCtD
Cefuroxime—Dyspnoea—Etoposide—muscle cancer	0.00295	0.00295	CcSEcCtD
Cefuroxime—Somnolence—Etoposide—muscle cancer	0.00294	0.00294	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Methotrexate—muscle cancer	0.00294	0.00294	CcSEcCtD
Cefuroxime—Vomiting—Dactinomycin—muscle cancer	0.00291	0.00291	CcSEcCtD
Cefuroxime—Bronchitis—Doxorubicin—muscle cancer	0.0029	0.0029	CcSEcCtD
Cefuroxime—Agranulocytosis—Methotrexate—muscle cancer	0.0029	0.0029	CcSEcCtD
Cefuroxime—Rash—Dactinomycin—muscle cancer	0.00288	0.00288	CcSEcCtD
Cefuroxime—Decreased appetite—Etoposide—muscle cancer	0.00288	0.00288	CcSEcCtD
Cefuroxime—Pancytopenia—Doxorubicin—muscle cancer	0.00287	0.00287	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Etoposide—muscle cancer	0.00286	0.00286	CcSEcCtD
Cefuroxime—Pain—Etoposide—muscle cancer	0.00283	0.00283	CcSEcCtD
Cefuroxime—Neutropenia—Doxorubicin—muscle cancer	0.00282	0.00282	CcSEcCtD
Cefuroxime—Dysuria—Doxorubicin—muscle cancer	0.00282	0.00282	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.00281	0.00281	CcSEcCtD
Cefuroxime—Haemoglobin—Methotrexate—muscle cancer	0.00281	0.00281	CcSEcCtD
Cefuroxime—Diarrhoea—Vincristine—muscle cancer	0.0028	0.0028	CcSEcCtD
Cefuroxime—Haemorrhage—Methotrexate—muscle cancer	0.00279	0.00279	CcSEcCtD
Cefuroxime—Hepatitis—Methotrexate—muscle cancer	0.00279	0.00279	CcSEcCtD
Cefuroxime—Urinary tract disorder—Methotrexate—muscle cancer	0.00276	0.00276	CcSEcCtD
Cefuroxime—Urethral disorder—Methotrexate—muscle cancer	0.00274	0.00274	CcSEcCtD
Cefuroxime—Nausea—Dactinomycin—muscle cancer	0.00272	0.00272	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Etoposide—muscle cancer	0.00271	0.00271	CcSEcCtD
Cefuroxime—Dizziness—Vincristine—muscle cancer	0.0027	0.0027	CcSEcCtD
Cefuroxime—Infestation NOS—Doxorubicin—muscle cancer	0.00269	0.00269	CcSEcCtD
Cefuroxime—Drowsiness—Doxorubicin—muscle cancer	0.00269	0.00269	CcSEcCtD
Cefuroxime—Infestation—Doxorubicin—muscle cancer	0.00269	0.00269	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00267	0.00267	CcSEcCtD
Cefuroxime—Renal failure—Doxorubicin—muscle cancer	0.00265	0.00265	CcSEcCtD
Cefuroxime—Erythema multiforme—Methotrexate—muscle cancer	0.00264	0.00264	CcSEcCtD
Cefuroxime—Urticaria—Etoposide—muscle cancer	0.00263	0.00263	CcSEcCtD
Cefuroxime—Stomatitis—Doxorubicin—muscle cancer	0.00262	0.00262	CcSEcCtD
Cefuroxime—Jaundice—Doxorubicin—muscle cancer	0.00262	0.00262	CcSEcCtD
Cefuroxime—Abdominal pain—Etoposide—muscle cancer	0.00262	0.00262	CcSEcCtD
Cefuroxime—Body temperature increased—Etoposide—muscle cancer	0.00262	0.00262	CcSEcCtD
Cefuroxime—Urinary tract infection—Doxorubicin—muscle cancer	0.00262	0.00262	CcSEcCtD
Cefuroxime—Vomiting—Vincristine—muscle cancer	0.0026	0.0026	CcSEcCtD
Cefuroxime—Sweating—Doxorubicin—muscle cancer	0.00258	0.00258	CcSEcCtD
Cefuroxime—Rash—Vincristine—muscle cancer	0.00258	0.00258	CcSEcCtD
Cefuroxime—Dermatitis—Vincristine—muscle cancer	0.00258	0.00258	CcSEcCtD
Cefuroxime—Headache—Vincristine—muscle cancer	0.00256	0.00256	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00255	0.00255	CcSEcCtD
Cefuroxime—Angiopathy—Methotrexate—muscle cancer	0.00253	0.00253	CcSEcCtD
Cefuroxime—Sinusitis—Doxorubicin—muscle cancer	0.00253	0.00253	CcSEcCtD
Cefuroxime—Immune system disorder—Methotrexate—muscle cancer	0.00252	0.00252	CcSEcCtD
Cefuroxime—Agranulocytosis—Doxorubicin—muscle cancer	0.00251	0.00251	CcSEcCtD
Cefuroxime—Chills—Methotrexate—muscle cancer	0.00251	0.00251	CcSEcCtD
Cefuroxime—Hypersensitivity—Etoposide—muscle cancer	0.00244	0.00244	CcSEcCtD
Cefuroxime—Erythema—Methotrexate—muscle cancer	0.00243	0.00243	CcSEcCtD
Cefuroxime—Haemoglobin—Doxorubicin—muscle cancer	0.00243	0.00243	CcSEcCtD
Cefuroxime—Nausea—Vincristine—muscle cancer	0.00243	0.00243	CcSEcCtD
Cefuroxime—Haemorrhage—Doxorubicin—muscle cancer	0.00242	0.00242	CcSEcCtD
Cefuroxime—Hepatitis—Doxorubicin—muscle cancer	0.00242	0.00242	CcSEcCtD
Cefuroxime—Urinary tract disorder—Doxorubicin—muscle cancer	0.00239	0.00239	CcSEcCtD
Cefuroxime—Urethral disorder—Doxorubicin—muscle cancer	0.00237	0.00237	CcSEcCtD
Cefuroxime—Pruritus—Etoposide—muscle cancer	0.00234	0.00234	CcSEcCtD
Cefuroxime—Erythema multiforme—Doxorubicin—muscle cancer	0.00229	0.00229	CcSEcCtD
Cefuroxime—Diarrhoea—Etoposide—muscle cancer	0.00227	0.00227	CcSEcCtD
Cefuroxime—Angiopathy—Doxorubicin—muscle cancer	0.00219	0.00219	CcSEcCtD
Cefuroxime—Dizziness—Etoposide—muscle cancer	0.00219	0.00219	CcSEcCtD
Cefuroxime—Immune system disorder—Doxorubicin—muscle cancer	0.00218	0.00218	CcSEcCtD
Cefuroxime—Leukopenia—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Cefuroxime—Chills—Doxorubicin—muscle cancer	0.00217	0.00217	CcSEcCtD
Cefuroxime—Cough—Methotrexate—muscle cancer	0.00212	0.00212	CcSEcCtD
Cefuroxime—Convulsion—Methotrexate—muscle cancer	0.00211	0.00211	CcSEcCtD
Cefuroxime—Vomiting—Etoposide—muscle cancer	0.00211	0.00211	CcSEcCtD
Cefuroxime—Erythema—Doxorubicin—muscle cancer	0.0021	0.0021	CcSEcCtD
Cefuroxime—Rash—Etoposide—muscle cancer	0.00209	0.00209	CcSEcCtD
Cefuroxime—Dermatitis—Etoposide—muscle cancer	0.00209	0.00209	CcSEcCtD
Cefuroxime—Headache—Etoposide—muscle cancer	0.00207	0.00207	CcSEcCtD
Cefuroxime—Flatulence—Doxorubicin—muscle cancer	0.00207	0.00207	CcSEcCtD
Cefuroxime—Arthralgia—Methotrexate—muscle cancer	0.00207	0.00207	CcSEcCtD
Cefuroxime—Chest pain—Methotrexate—muscle cancer	0.00207	0.00207	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00205	0.00205	CcSEcCtD
Cefuroxime—Muscle spasms—Doxorubicin—muscle cancer	0.00202	0.00202	CcSEcCtD
Cefuroxime—Anaphylactic shock—Methotrexate—muscle cancer	0.00198	0.00198	CcSEcCtD
Cefuroxime—Nausea—Etoposide—muscle cancer	0.00197	0.00197	CcSEcCtD
Cefuroxime—Thrombocytopenia—Methotrexate—muscle cancer	0.00194	0.00194	CcSEcCtD
Cefuroxime—Agitation—Doxorubicin—muscle cancer	0.00193	0.00193	CcSEcCtD
Cefuroxime—Skin disorder—Methotrexate—muscle cancer	0.00193	0.00193	CcSEcCtD
Cefuroxime—Hyperhidrosis—Methotrexate—muscle cancer	0.00192	0.00192	CcSEcCtD
Cefuroxime—Anorexia—Methotrexate—muscle cancer	0.00189	0.00189	CcSEcCtD
Cefuroxime—Leukopenia—Doxorubicin—muscle cancer	0.00188	0.00188	CcSEcCtD
Cefuroxime—Palpitations—Doxorubicin—muscle cancer	0.00186	0.00186	CcSEcCtD
Cefuroxime—Cough—Doxorubicin—muscle cancer	0.00184	0.00184	CcSEcCtD
Cefuroxime—Convulsion—Doxorubicin—muscle cancer	0.00182	0.00182	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00181	0.00181	CcSEcCtD
Cefuroxime—Arthralgia—Doxorubicin—muscle cancer	0.00179	0.00179	CcSEcCtD
Cefuroxime—Chest pain—Doxorubicin—muscle cancer	0.00179	0.00179	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00178	0.00178	CcSEcCtD
Cefuroxime—Dyspnoea—Methotrexate—muscle cancer	0.00177	0.00177	CcSEcCtD
Cefuroxime—Somnolence—Methotrexate—muscle cancer	0.00176	0.00176	CcSEcCtD
Cefuroxime—Dyspepsia—Methotrexate—muscle cancer	0.00175	0.00175	CcSEcCtD
Cefuroxime—Decreased appetite—Methotrexate—muscle cancer	0.00172	0.00172	CcSEcCtD
Cefuroxime—Anaphylactic shock—Doxorubicin—muscle cancer	0.00172	0.00172	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00171	0.00171	CcSEcCtD
Cefuroxime—Pain—Methotrexate—muscle cancer	0.0017	0.0017	CcSEcCtD
Cefuroxime—Thrombocytopenia—Doxorubicin—muscle cancer	0.00168	0.00168	CcSEcCtD
Cefuroxime—Tachycardia—Doxorubicin—muscle cancer	0.00168	0.00168	CcSEcCtD
Cefuroxime—Skin disorder—Doxorubicin—muscle cancer	0.00167	0.00167	CcSEcCtD
Cefuroxime—Hyperhidrosis—Doxorubicin—muscle cancer	0.00166	0.00166	CcSEcCtD
Cefuroxime—Anorexia—Doxorubicin—muscle cancer	0.00164	0.00164	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Methotrexate—muscle cancer	0.00162	0.00162	CcSEcCtD
Cefuroxime—Urticaria—Methotrexate—muscle cancer	0.00158	0.00158	CcSEcCtD
Cefuroxime—Abdominal pain—Methotrexate—muscle cancer	0.00157	0.00157	CcSEcCtD
Cefuroxime—Body temperature increased—Methotrexate—muscle cancer	0.00157	0.00157	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00156	0.00156	CcSEcCtD
Cefuroxime—Dyspnoea—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Cefuroxime—Somnolence—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Cefuroxime—Dyspepsia—Doxorubicin—muscle cancer	0.00151	0.00151	CcSEcCtD
Cefuroxime—Decreased appetite—Doxorubicin—muscle cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00148	0.00148	CcSEcCtD
Cefuroxime—Pain—Doxorubicin—muscle cancer	0.00147	0.00147	CcSEcCtD
Cefuroxime—Hypersensitivity—Methotrexate—muscle cancer	0.00146	0.00146	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Doxorubicin—muscle cancer	0.0014	0.0014	CcSEcCtD
Cefuroxime—Pruritus—Methotrexate—muscle cancer	0.0014	0.0014	CcSEcCtD
Cefuroxime—Urticaria—Doxorubicin—muscle cancer	0.00136	0.00136	CcSEcCtD
Cefuroxime—Abdominal pain—Doxorubicin—muscle cancer	0.00136	0.00136	CcSEcCtD
Cefuroxime—Body temperature increased—Doxorubicin—muscle cancer	0.00136	0.00136	CcSEcCtD
Cefuroxime—Diarrhoea—Methotrexate—muscle cancer	0.00136	0.00136	CcSEcCtD
Cefuroxime—Dizziness—Methotrexate—muscle cancer	0.00131	0.00131	CcSEcCtD
Cefuroxime—Hypersensitivity—Doxorubicin—muscle cancer	0.00127	0.00127	CcSEcCtD
Cefuroxime—Vomiting—Methotrexate—muscle cancer	0.00126	0.00126	CcSEcCtD
Cefuroxime—Rash—Methotrexate—muscle cancer	0.00125	0.00125	CcSEcCtD
Cefuroxime—Dermatitis—Methotrexate—muscle cancer	0.00125	0.00125	CcSEcCtD
Cefuroxime—Headache—Methotrexate—muscle cancer	0.00124	0.00124	CcSEcCtD
Cefuroxime—Pruritus—Doxorubicin—muscle cancer	0.00122	0.00122	CcSEcCtD
Cefuroxime—Nausea—Methotrexate—muscle cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Diarrhoea—Doxorubicin—muscle cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Dizziness—Doxorubicin—muscle cancer	0.00114	0.00114	CcSEcCtD
Cefuroxime—Vomiting—Doxorubicin—muscle cancer	0.00109	0.00109	CcSEcCtD
Cefuroxime—Rash—Doxorubicin—muscle cancer	0.00108	0.00108	CcSEcCtD
Cefuroxime—Dermatitis—Doxorubicin—muscle cancer	0.00108	0.00108	CcSEcCtD
Cefuroxime—Headache—Doxorubicin—muscle cancer	0.00108	0.00108	CcSEcCtD
Cefuroxime—Nausea—Doxorubicin—muscle cancer	0.00102	0.00102	CcSEcCtD
